Lack of expression and function of erythropoietin receptors in the kidney

Nephrology Dialysis Transplantation

Volumn 27, Issue 7, 2012, Pages 2733-2745

  Elliott, Steve ^a   Busse, Leigh ^a   Swift, Susan ^a   McCaffery, Ian ^a   Rossi, John ^a   Kassner, Paul ^a   Begley, C Glenn ^a  

^a AMGEN INC   (United States)

Author keywords

erythropoiesis stimulating agents; erythropoietin; erythropoietin receptor; kidney; tissue protection

Indexed keywords

ERYTHROPOIETIN RECEPTOR; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CELL LINEAGE; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CELL VIABILITY; CONTROLLED STUDY; CROSS REACTION; GENE CONTROL; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CELL; LIMIT OF DETECTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION;

BLOTTING, WESTERN; CELL PROLIFERATION; CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIETIN; FLOW CYTOMETRY; HUMANS; KIDNEY; KIDNEY DISEASES; MEGAKARYOCYTES; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ERYTHROPOIETIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84864406372     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr698     Document Type: Article

References (71)

1. Bahlmann FH, Fliser D. Erythropoietin and renoprotection. Curr Opin Nephrol Hypertens 2009; 18: 15-20.
2. Jelkmann W, Bohlius J, Hallek M et al. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 2008; 67: 39-61.
3. Singh AK. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?. Curr Opin Nephrol Hypertens 2010; 19: 420-424.
4. Elliott S, Busse L, Bass MB et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006; 107: 1892-1895.
5. Brown WM, Maxwell P, Graham AN et al. Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem Cells 2007; 25: 718-722.
6. Kirkeby A, van BJ, Nielsen J et al. Functional and immunochemical characterisation of different antibodies against the erythropoietin receptor. J Neurosci Methods 2007; 164: 50-58.
7. Sinclair AM, Coxon A, McCaffery I et al. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 2010; 115: 4264-4272.
8. Baltar J, Moran N, Ortega F et al. Erythropoietin safety and efficacy in chronic allograft nephropathy. Transplant Proc 2007; 39: 2245-2247.
9. Fernandez LM, Marcen R, Villafruela J et al. Effect of rHuEpo therapy in dialysis patients on endogenous erythropoietin synthesis after renal transplantation. Nephron 1996; 73: 54-57.
10. Kamar N, Reboux A-H, Cointault O et al. Impact of very early high doses of recombinant erythropoietin on anemia and allograft function in de novo kidney-transplant patients. Transplant Int 2010; 23: 277-284.
11. Martinez F, Kamar N, Pallet N et al. High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: results of the Neo-PDGF study. Am J Transplant 2010; 10: 1704-1709.
12. Mohiuddin MK, El-Asir L, Gupta A et al. Perioperative erythropoietin efficacy in renal transplantation. Transplant Proc 2007; 39: 132-134.
13. VanBiesen W, Vanholder R, Veys N et al. Efficacy of erythropoietin administration in the treatment of anemia immediately after renal transplantation. Transplantation 2005; 79: 367-368.
14. Endre ZH, Walker RJ, Pickering JW et al. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 2010; 77: 1020-1030.
15. Elliott S, Busse L, McCaffery I et al. Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells. J Immunol Methods 2010; 352: 126-139.
16. Swift S, Ellison AR, Kassner P et al. Absence of functional EpoR expression in human tumor cell lines. Blood 2010; 115: 4254-4263.
17. Sinclair AM, Rogers N, Busse L et al. Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. Br J Cancer 2008; 98: 1059-1067.
18. Juul SE, Yachnis AT, Christensen RD. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 1998; 52: 235-249.
19. Komatsu N, Yamamoto M, Fujita H et al. Establishment and characterization of an erythropoietin-dependent subline, UT-7/Epo, derived from human leukemia cell line, UT-7. Blood 1993; 82: 456-464.
20. Broudy VC, Lin N, Egrie J et al. Identification of the receptor for erythropoietin on human and murine erythroleukemia cells and modulation by phorbol ester and dimethyl sulfoxide. Proc Natl Acad Sci USA 1988; 85: 6513-6517.
21. Hahn WC, Counter CM, Lundberg AS et al. Creation of human tumour cells with defined genetic elements. Nature 1999; 400: 464-468.
22. Divoky V, Liu Z, Ryan TM et al. Mouse model of congenital polycythemia: homologous replacement of murine gene by mutant human erythropoietin receptor gene. Proc Natl Acad Sci USA 2001; 98: 986-991.
23. Carter-Su C, Smit LS. Signaling via JAK tyrosine kinases: growth hormone receptor as a model system. Recent Prog Horm Res 1982; 53: 61-82.
24. Neumann D, Wikstrom L, Watowich SS et al. Intermediates in degradation of the erythropoietin receptor accumulate and are degraded in lysosomes. J Biol Chem 1993; 268: 13639-13649.
25. Hilton DJ, Watowich SS, Murray PJ et al. Increased cell surface expression and enhanced folding in the endoplasmic reticulum of a mutant erythropoietin receptor. Proc Natl Acad Sci USA 1995; 92: 190-194.
26. Mayeux P, Billat C, Jacquot R. The erythropoietin receptor of rat erythroid progenitor cells. Characterization and affinity crosslinkage. J Biol Chem 1987; 262: 13985-13990.
27. Sawada K, Krantz SB, Sawyer ST et al. Quantitation of specific binding of erythropoietin to human erythroid colony-forming cells. J Cell Physiol 1988; 137: 337-345.
28. Sawada K, Krantz SB, Kans JS et al. Purification of human erythroid colony-forming units and demonstration of specific binding of erythropoietin. J Clin Invest 1987; 80: 357-366.
29. Wognum AW, Lansdorp PM, Humphries RK et al. Detection and isolation of the erythropoietin receptor using biotinylated erythropoietin. Blood 1990; 76: 697-705.
30. Billia F, Barbara M, McEwen J et al. Resolution of pluripotential intermediates in murine hematopoietic differentiation by global complementary DNA amplification from single cells: confirmation of assignments by expression profiling of cytokine receptor transcripts. Blood 2001; 97: 2257-2268.
31. Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 2001; 108: 785-791.
32. Smith MA, Morton CL, Phelps D et al. SK-NEP-1 and Rh1 are Ewing family tumor lines. Pediatr Blood Cancer 2008; 50: 703-706.
33. Hagstrom L, Agbulut O, El-Hasnaoui-Saadani R et al. Epo is relevant neither for microvascular formation nor for the new formation and maintenance of mice skeletal muscle fibres in both normoxia and hypoxia. J Biomed Biotechnol 2010; 2010: 137817
34. Banerjee D, Rodriguez M, Nag M et al. Exposure of endothelial cells to recombinant human erythropoietin induces nitric oxide synthase activity. Kidney Int 2000; 57: 1895-1904.
35. D'Andrea AD, Lodish HF, Wong GG. Expression cloning of the murine erythropoietin receptor. Cell 1989; 57: 277-285.
36. Sinclair AM, Todd MD, Forsythe K et al. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 2007; 110: 477-488.
37. Berdel WE, Danhauser-Riedl S, Oberberg D et al. Effects of hematopoietic growth factors on malignant nonhematopoietic cells. Semin Oncol 1992; 192 Suppl 441-45.
38. Liu WM, Powles T, Shamash J et al. Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity. Oncogene 2004; 23: 981-990.
39. Mundt D, Berger MR, Bode G. Effect of recombinant human erythropoietin on the growth of human tumor cell lines in vitro. Microtitertec-tetrazolium assay. Arzneimittelforschung 1992; 42: 92-95.
40. Kataoka M, Moriya Y, Moriguchi Y et al. Effect of erythropoietin on human tumor growth in xenograft models. Mol Med Report 2010; 3: 95-101.
41. Suzuki N, Ohneda O, Takahashi S et al. Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood 2002; 100: 2279-2288.
42. Acs G, Zhang PJ, Rebbeck TR et al. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 2002; 95: 969-981.
43. Acs G, Chen M, Xu X et al. Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells. Cancer Lett 2004; 214: 243-251.
44. Paragh G, Kumar SM, Rakosy Z et al. RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells. Am J Pathol 2009; 174: 1504-1514.
45. Jeong JY, Feldman L, Solar P et al. Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells. Int J Cancer 2008; 122: 274-280.
46. Jeong JY, Hoxhaj G, Socha AL et al. An erythropoietin autocrine/paracrine axis modulates the growth and survival of human prostate cancer cells. Mol Cancer Res 2009; 7: 1150-1157.
47. Binder C, Lafayette A, Archibeque I et al. Optimization and utilization of the SureFire phospho-STAT5 assay for a cell-based screening campaign. Assay Drug Dev Technol 2008; 6: 27-37.
48. Jegalian AG, Acurio A, Dranoff G et al. Erythropoietin receptor haploinsufficiency and in vivo interplay with granulocyte-macrophage colony-stimulating factor and interleukin 3. Blood 2002; 99: 2603-2605.
49. McArthur GA, Longmore GD, Klingler K et al. Lineage-restricted recruitment of immature hematopoietic progenitor cells in response to Epo after normal hematopoietic cell transfection with EpoR. Exp Hematol 1995; 23: 645-654.
50. Um M, Lodish HF. Antiapoptotic effects of erythropoietin in differentiated neuroblastoma SH-SY5Y cells require activation of both the STAT5 and AKT signaling pathways. J Biol Chem 2006; 281: 5648-5656.
51. Laugsch M, Metzen E, Svensson T et al. Lack of functional erythropoietin receptors of cancer cell lines. Int J Cancer 2008; 122: 1005-1011.
52. D'Andrea AD, Jones SS. Activation of the erythropoietin receptor in stable lymphoid and myeloid transfectants. Semin Hematol 1991; 28: 152-157.
53. Migliaccio AR, Migliaccio G, D'Andrea A et al. Response to erythropoietin in erythroid subclones of the factor-dependent cell line 32D is determined by translocation of the erythropoietin receptor to the cell surface. Proc Natl Acad Sci USA 1991; 88: 11086-11090.
54. Gaffen SL, Lai SY, Longmore GD et al. Genetic evidence for an additional factor required for erythropoietin-induced signal transduction. Blood 1999; 94: 74-86.
55. Longmore GD, Lodish HF. An activating mutation in the murine erythropoietin receptor induces erythroleukemia in mice: a cytokine receptor superfamily oncogene. Cell 1991; 67: 1089-1102.
56. Layon ME, Ackley CJ, West RJ et al. Expression of GATA-1 in a non-hematopoietic cell line induces beta-globin locus control region chromatin structure remodeling and an erythroid pattern of gene expression. J Mol Biol 2007; 366: 737-744.
57. Sakamoto H, Kitamura T, Yoshimura A. Mitogen-activated protein kinase plays an essential role in the erythropoietin-dependent proliferation of CTLL-2 cells. J Biol Chem 2000; 275: 35857-35862.
58. Dainiak N, Kreczko S, Cohen A et al. Primary human marrow cultures for erythroid bursts in a serum-substituted system. Exp Hematol 1985; 13: 1073-1079.
59. Swift S, Elliott S, Sinclair A et al. Erythropoietin receptor in ovarian cancer cells-Letter. Mol Cancer Ther 2010; 9: 1070-1071.
60. Harmey JH, Bucana CD, Lu W et al. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 2002; 101: 415-422.
61. Li S, Fan SX, McKenna TM. Vascular smooth muscle cells on Matrigel as a model for LPS-induced hypocontractility and NO formation. Am J Physiol 1997; 272: H576-H584.
62. Quesenberry P, Levin J, Zuckerman K et al. Stem cell migration induced by erythropoietin or haemolytic anaemia: the effects of actinomycin and endotoxin contamination of erythropoietin preparations. Br J Haematol 1979; 41: 253-269.
63. Katavetin P, Tungsanga K, Eiam-Ong S et al. Antioxidative effects of erythropoietin. Kidney Int 2007; 72: S10-S15.
64. Bramey T, Freitag P, Fandrey J et al. No evidence for protective erythropoietin alpha signalling in rat hepatocytes. BMC Gastroenterol 2009; 9: 26
65. Singbrant S, Russell MR, Jovic et al. Erythropoietin couples erythropoiesis, B lymphopoiesis, and bone homeostasis within the bone marrow microenvironment. Blood 2011; 117: 5631-5642.
66. Brines M, Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 2006; 70: 246-250.
67. Um M, Gross AW, Lodish HF. A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell Signal 2007; 19: 634-645.
68. Scott CL, Robb L, Papaevangeliou B et al. Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3- specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor, or stem cell factor. Blood 2000; 96: 1588-1590.
69. Pinzon A, Marcillo A, Pabon D et al. A re-assessment of erythropoietin as a neuroprotective agent following rat spinal cord compression or contusion injury. Exp Neurol 2008; 213: 129-136.
70. French CJ, Zaman AK, Sobel BE. Failure of erythropoietin to render jeopardized ischemic myocardium amenable to incremental salvage by early reperfusion. Coron Artery Dis 2009; 20: 295-299.
71. Solling C, Christensen AT, Nygaard U et al. Erythropoietin does not attenuate renal dysfunction or inflammation in a porcine model of endotoxemia. Acta Anaesthesiol Scand 2011; 55: 411-421.